Daiichi Sankyo has partnered with startup AgonOx to develop novel drugs against an undisclosed immuno-oncology target.

Amgen has become the latest big-name drugmaker to strike a deal to access Nuevolution’s discovery platform.

Gene therapy player bluebird bio has partnered with German biotech Medigene to develop and commercialize T cell receptor (TCR) immunotherapies against four…

Roche’s Genentech is pairing up with Hanmi Pharmaceutical to gain access to its Phase I pan-RAF inhibitor.

Acceleron has brought in a top commercial exec from Bayer, Habib Dable, to lead the company as it aims to plan for a marketed product.

Johnson & Johnson’s Janssen has licensed two early oncology assets to Tracon Pharmaceuticals through Phase I/II development, then the pharma has the…

Shire has returned rights to the two biosimilars that Baxalta had in development.

Genentech has commited $310 million in upfront and near-term payments to BioNTech to partner on its mRNA cancer vaccine platform.